LAG-3 has spent a decade being exploited almost exclusively as a checkpoint to release — block it, and exhausted T cells revive against tumors. Immutep is running the mechanism in reverse. Interim Phase I data for IMP761, presented at EULAR 2026 in London, show that a LAG-3 agonist antibody can meaningfully suppress T-cell activity in healthy humans, with statistically significant pharmacodynamic effects at 7 mg/kg in a placebo-controlled, double-blind setting (p = 0.029 for skin blood perfusion). That is not a threshold-clearing footnote; it is the first clinical confirmation that agonizing LAG-3 works as a pharmacological strategy in people, not just in preclinical models.
The study design deserves scrutiny because it does the heavy lifting here. Immutep used the keyhole limpet hemocyanin (KLH) challenge model — a pooled-analysis-validated neoantigen immune response system administered in healthy volunteers — to generate early pharmacodynamic readouts without waiting for a patient population. Across cohorts from 0.9 mg/kg to 7 mg/kg, IMP761 reduced local inflammatory responses and attenuated T-cell activity versus placebo, with the primary endpoint — safety and tolerability in the single ascending dose portion — met at every level tested. Pharmacokinetics from single doses support a once-per-four-week schedule, which matters enormously for patient convenience in chronic autoimmune indications.
The strategic context is sharper when you consider where Immutep’s LAG-3 cancer program sits: its Phase III TACTI-004 trial in non-small cell lung cancersmall cell lung cancer was terminated, compressing the company’s near-term value narrative onto IMP761 and the autoimmune pivot. That pivot lands in a crowded rheumatoid arthritis field anchored by five FDA-approved TNF inhibitors and an expanding biosimilar wave, but IMP761’s mechanism — selectively targeting activated T cells at inflammation sites while, in theory, preserving systemic immune function — is mechanistically distinct from TNF blockade. Researchers demonstrated last year that LAG-3 inhibits T-cell activity by positioning near the TCR complex, providing a structural rationale for why agonism could enforce peripheral tolerance without broad immunosuppression.
The single number worth tracking as this program advances toward Phase II is whether the 7 mg/kg pharmacodynamic signal — the dose that crossed the significance threshold — holds up when the KLH model is replaced by an actual autoimmune patient population with established, pathological T-cell infiltration. Healthy-volunteer models confirm mechanism; they do not confirm magnitude in disease tissue. That translation is the next genuine test.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
